全文获取类型
收费全文 | 1012928篇 |
免费 | 74539篇 |
国内免费 | 11321篇 |
专业分类
耳鼻咽喉 | 13442篇 |
儿科学 | 29747篇 |
妇产科学 | 27275篇 |
基础医学 | 140005篇 |
口腔科学 | 26568篇 |
临床医学 | 90299篇 |
内科学 | 200186篇 |
皮肤病学 | 20145篇 |
神经病学 | 77423篇 |
特种医学 | 40650篇 |
外国民族医学 | 414篇 |
外科学 | 153778篇 |
综合类 | 39580篇 |
现状与发展 | 40篇 |
一般理论 | 253篇 |
预防医学 | 72326篇 |
眼科学 | 23395篇 |
药学 | 75769篇 |
95篇 | |
中国医学 | 8846篇 |
肿瘤学 | 58552篇 |
出版年
2021年 | 12146篇 |
2020年 | 8395篇 |
2019年 | 10343篇 |
2018年 | 13154篇 |
2017年 | 10813篇 |
2016年 | 11161篇 |
2015年 | 14090篇 |
2014年 | 18936篇 |
2013年 | 24940篇 |
2012年 | 34012篇 |
2011年 | 36521篇 |
2010年 | 22410篇 |
2009年 | 20384篇 |
2008年 | 32057篇 |
2007年 | 33584篇 |
2006年 | 33606篇 |
2005年 | 33222篇 |
2004年 | 30030篇 |
2003年 | 28896篇 |
2002年 | 27976篇 |
2001年 | 43863篇 |
2000年 | 45205篇 |
1999年 | 39158篇 |
1998年 | 11922篇 |
1997年 | 11140篇 |
1996年 | 10614篇 |
1995年 | 9892篇 |
1994年 | 9329篇 |
1993年 | 8355篇 |
1992年 | 29111篇 |
1991年 | 27715篇 |
1990年 | 27032篇 |
1989年 | 25935篇 |
1988年 | 24041篇 |
1987年 | 23594篇 |
1986年 | 22613篇 |
1985年 | 21413篇 |
1984年 | 15923篇 |
1983年 | 13569篇 |
1982年 | 8142篇 |
1979年 | 14638篇 |
1978年 | 10208篇 |
1977年 | 8627篇 |
1976年 | 8147篇 |
1975年 | 8959篇 |
1974年 | 10698篇 |
1973年 | 10182篇 |
1972年 | 9661篇 |
1971年 | 8917篇 |
1970年 | 8584篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
111.
T.F.A. Lees L. Bogdashich D. Godden 《The British journal of oral & maxillofacial surgery》2021,59(1):e9-e12
Fibroepithelial polyps (FEPs) are common, benign intraoral lesions that tend to develop slowly at predictable sites, often in response to local irritation or trauma. Historical precedent often results in referral to oral and maxillofacial surgery (OMFS) departments for biopsy, often irrespective of symptoms, and histological assessment. OMFS and pathology services are struggling to cope with an increasing workload that will potentially lead to widespread delays to diagnosis and treatment. Over the past 20 years, clinical pathways and guidance have been developed to ensure that healthcare interventions, such as the removal of third molars, tonsils, skin tags, and benign moles, are evidence-based, have a net patient benefit, and ensure the best use of finite NHS resources. However, no such guidance exists for intraoral lesions and we regard this as an oversight. We analysed the removal of 682 FEPs over a seven-year period and report sensitivities of 92.4% for a “confirmed clinical suspicion of an FEP” and 99.7% for a “confirmed clinical suspicion of a benign diagnosis”. The incidence of non-benign disease was 0.3%. Primary care dentists should be able to diagnose and monitor FEPs and refer only if symptoms are serious or in high-risk patients or sites. Adopting this practice across the UK could free up to 1825 four-hour OMFS clinics, 405 hours of consultant histopathologists’ time, and recurring savings to the NHS estimated to be in the region of £620 000/annum. We believe that the removal of FEPs should be reclassified as an “intervention not normally funded”, and the time and resources put to better use treating patients with lesions of questionable pathology. 相似文献
112.
Yang Chih-Hsiang Wang Shirlene Wang Wei-Lin Belcher Britni R. Dunton Genevieve F. 《Journal of behavioral medicine》2022,45(5):702-715
Journal of Behavioral Medicine - Understanding associations between mothers’ and children’s physical activity and sedentary behavior on more fine-grained timescales can provide insights... 相似文献
113.
114.
In both adults and children with diabetes, technologies such as continuous subcutaneous insulin infusion using insulin pumps and continuous glucose monitoring can help improve diabetes control, reduce hypoglycaemia and improve quality of life. Access to these technologies in the UK is very variable. Some technologies are recommended by the National Institute for Health and Care Excellence, while others have not been appraised, and new technologies are emerging all the time. Additionally, different guidelines for adults and children further complicate access to diabetes technology in the transition from paediatric to adult care. Against this background, Diabetes UK and NHS England have brought together a multidisciplinary group of experts, including clinicians and people with diabetes, to develop this consensus guideline, combining the different technologies into a common pathway to aid clinical and policy decision‐making. We created a pathway that supports the incremental addition of technology as monotherapy and then dual therapy in the same way that we incrementally add in therapeutic agents to support people with Type 2 diabetes to achieve their personalized glycaemic targets. The pathway emphasizes the importance of structured education, specialist support and appropriate access to psychological therapies, as essential pillars for optimized use of diabetes‐related technology, and recommends the re‐evaluation of its use when the individual is unable either to use the technology appropriately or to achieve the intended outcomes. This pathway is endorsed by UK‐wide clinical and patient associations and we recommend that providers and commissioners use it to ensure the right individual with diabetes has access to the right technology in a timely way to help achieve better outcomes. 相似文献
115.
目的 通过UHPLC-Q-TOF-MS代谢组学探讨艾灸关元穴对老年大鼠肾代谢物的影响,进而为艾灸关元穴的作用机制提供参考。方法 将8月龄SD雄性大鼠设为成年对照组(8只),21月龄SD雄性大鼠随机分为老年对照组(8只)、老年金匮肾气丸组(7只)、老年艾灸组(8只)。老年金匮肾气丸组每日按体重给药,老年艾灸组每日艾灸关元穴15 min,均每周5天。实验持续13周后检测大鼠肾组织线粒体呼吸耗氧速率、琥珀酸脱氢酶(SDH)活性以及血清肾功能指标,观察肾脏病理变化,结合UHPLC-Q-TOF-MS技术对大鼠的肾组织进行代谢轮廓分析,筛选代谢差异物并进行鉴定。结果 与老年对照组比较,老年艾灸组大鼠肾线粒体的呼吸耗氧速率和SDH酶的活力显著提高(P<0.01)。代谢组学结果显示,肾组织中筛选出13个共同差异化合物,分别是丁酸十二烷基酯、亚油酰胺、5-甲基四氢叶酸、PC(16∶0/22∶5(7Z,10Z,13Z,16Z,19Z))、6,8-二羟基嘌呤、1,2,3-丙烷三羧酸、3-(4-甲氧基苯基)-2-氧代丙酸、吲哚-3-乙酰甘氨酸、亚麻油酸、9,10-环氧十八烷酸、二十二碳五烯酸(22n-6)、牛磺胆酸、LysoPS (18∶0/0∶0)。结论 艾灸关元穴可通过调控老年大鼠的牛磺酸和亚牛磺酸代谢、α-亚麻酸代谢、亚油酸代谢、甘油磷脂代谢来调节肾的能量代谢。 相似文献
116.
Familial risk and heritability of intellectual disability: a population-based cohort study in Sweden
117.
118.
目的 前房注射卡波姆建立大鼠高眼压模型,观察卡波姆升眼压效果及对大鼠眼前节和视网膜的影响。方法 随机选取30只SD大鼠,注射前3 d早晚测量基线眼压。右眼定为实验眼,左眼定为对照眼,右眼放出房水后将30 μL的5 g·L-1卡波姆混悬液注入前房,每日早10时、晚22时在大鼠清醒状态下测量眼压。每周进行双眼眼前节照相并对比。4周末处死26只大鼠(另4只持续观察眼压变化至注射后9周)并取双眼眼球行HE染色,观察实验眼与对照眼视网膜形态,对比视网膜厚度及房角形态。结果 注射前,实验眼白天和夜间眼压分别为(11.10±0.90)mmHg(1 kPa=7.5 mmHg)和(11.92±1.07)mmHg,对照眼分别为(11.22±1.07)mmHg和(11.76±1.08)mmHg;实验眼与对照眼相比,白天、夜间眼压差异均无统计学意义(均为 P>0.05);白天与夜间眼压相比,实验眼、对照眼差异均有统计学意义(均为P<0.05)。卡波姆在前房中呈现出弥散型和沉积型两种存在方式,弥散型和沉积型大鼠1周内眼压分别为(17.83±3.54)mmHg和(13.00±1.55)mmHg,两者相比差异具有统计学意义(P<0.05)。注射后第1天至第19天,实验眼与对照眼白天眼压相比差异均具有统计学意义(均为P<0.05);注射后第1天至第27天,实验眼与对照眼夜间眼压相比差异均具有统计学意义(均为P<0.05)。实验眼视网膜形态发生改变,注射后4周视网膜厚度为(254.70±21.80)μm,与对照眼的(346.73±24.63)μm相比,差异有统计学意义(P=0.00)。实验眼前房充满卡波姆及虹膜的混合成分,紧贴角膜内皮并延伸至房角,堵塞小梁网结构,正常虹膜形态消失;对照眼房角形态正常。结论 前房注射卡波姆建立大鼠高眼压模型,可维持高眼压4周以上,昼夜眼压差异较为明显,夜间眼压较白天更高,4周后视网膜出现高眼压损伤后的表现。 相似文献
119.
Joseph F. Levy Rahul Khairnar Alexander V. Louie Timothy N. Showalter C. Daniel Mullins Mark V. Mishra 《Practical radiation oncology》2019,9(2):e172-e179
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献120.